A large-scale evaluation of these cells in 228 glioma-suspect patients demonstrated that for the detection of a cerebral lesion sensitivity of 81% and specificity of 85% can be reached with a CO of 0.6% GFAP+CD16+ monocytes. The gene discussed is GFAP; the disease is central nervous system cancer.